Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CBLB | Q13191 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18785836 | 0.83 | LMNA (0.36) | ALDH1A1HSD17B10ALOX15CBLBLMNA | |
| SCHEMBL5962387 | 0.71 | CBLB (0.50) | ALDH1A1HSD17B10ALOX15CBLBLMNA | |
| SCHEMBL4179251 | 0.66 | ALDH1A1 (0.44) | ALDH1A1HSD17B10LMNAL3MBTL1KDM4E | |
| SCHEMBL16018117 | 0.66 | ALDH1A1 (0.46) | ALDH1A1HSD17B10ALOX15CBLBLMNA | |
| SCHEMBL14969208 | 0.66 | ALDH1A1 (0.53) | ALDH1A1HSD17B10LMNAL3MBTL1KDM4E | |
| SCHEMBL969717 | 0.65 | GCK (0.34) | ALDH1A1HSD17B10ALOX15CBLBLMNA | |
| SCHEMBL10401904 | 0.65 | CBLB (0.44) | ALDH1A1HSD17B10ALOX15CBLBL3MBTL1 | |
| SCHEMBL4378220 | 0.65 | ALDH1A1 (0.49) | ALDH1A1HSD17B10LMNAL3MBTL1KDM4E | |
| SCHEMBL10403528 | 0.65 | CBLB (0.44) | ALDH1A1HSD17B10ALOX15CBLBL3MBTL1 | |
| SCHEMBL10447746 | 0.64 | ALDH1A1 (0.54) | ALDH1A1LMNARAB9AKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10729738-B2 | Hindered disulfide drug conjugates | GENENTECH, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10172821-B2 | Histone deacetylase inhibitors | President & Fellows of Harvard College Dana-Farber Cancer Institute, Inc. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9724321-B2 | Histone deacetylase inhibitors | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160143874-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-26 | — | — | US | disclosed |
| US-9199923-B2 | Histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150038581-A1 | HISTONE DEACETYLASE INHIBITORS | Harvard University & Medical School | 2015-02-05 | — | — | US | disclosed |
| US-20140213620-A1 | HISTONE DEACETYLASE INHIBITORS | BRADNER JAMES ELLIOT (US) | 2014-07-31 | — | — | US | disclosed |
| US-8754237-B2 | Bifunctional histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130018103-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8222423-B2 | Bifunctional histone deacetylase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018103-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | ALDH1A1 786/4885HSD17B10 410/4885ALOX15 4541/4885 |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | ALDH1A1 269/4885HSD17B10 2559/4885ALOX15 4110/4885 |
| US-20140213620-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | ALDH1A1 764/4885HSD17B10 279/4885ALOX15 1002/4885 |
| US-20160143874-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | ALDH1A1 955/4885HSD17B10 379/4885ALOX15 1563/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | ALDH1A1 269/4885HSD17B10 2559/4885ALOX15 4110/4885 |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | ALDH1A1 786/4885HSD17B10 410/4885ALOX15 4541/4885 |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | ALDH1A1 764/4885HSD17B10 279/4885ALOX15 1002/4885 |
| US-20150038581-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | ALDH1A1 764/4885HSD17B10 279/4885ALOX15 1002/4885 |
| US-10729738-B2 | Hindered disulfide drug conjugates | STS, TST, SCLY | ALDH1A1 143/4885HSD17B10 567/4885ALOX15 2310/4885 |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | STS, TST, SCLY | ALDH1A1 143/4885HSD17B10 567/4885ALOX15 2310/4885 |
| US-10172821-B2 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC7 | ALDH1A1 764/4885HSD17B10 279/4885ALOX15 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.